Clinical trial data for Lexicon Pharmaceuticals’ type 1 diabetes drug is performing well, significantly reducing the marker A1C in 24 weeks as well as through the first full year of treatment, even helping patients lose weight and lower blood pressure, according to Endpoints News. But before the drug is cleared for marketing by the Food and Drug Administration (FDA), the drug company will have to prove that it is safe. The drug is a combination SGLT1/SGLT2 inhibitor called sotagliflozin, which targets SGLT2 within the kidneys as well as SGLT-1 inhibitors located in the intestinal tract. Both work to block glucose ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.